Q2 2025 Earnings Call Transcript August 8, 2025 ANI Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $1.8, ...

ANI Pharmaceuticals (ANIP) reported $211.37 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 53.1%. EPS of $1.80 for the same period compares to $1.02 a ...

ANI Pharmaceuticals Inc (ANIP) reports a robust quarter with significant revenue growth and upward revisions in 2025 guidance ...

Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis ...

Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on an organic basisTotal Rare Disease quarterly net revenues of ...

Iluvien for diabetic macular edema demonstrated longer-lasting intervals between injections and noninferior visual acuity ...

We are pleased to share the results at the ASRS meeting and look forward to presenting additional data in the future to further inform clinical decision-making.” For safety, ILUVIEN was well tolerated ...

PRINCETON, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANIP) today announced results from the NEW DAY clinical trial of ILUVIEN® (fluocinolone acetonide intravitreal ...

For safety, ILUVIEN was well tolerated in the trial, with a safety profile that is consistent with data from prior ILUVIEN clinical trials and real-world use.

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study Enrolled Treatment-Naïve, or Almost Naïve, Patients with DME ...

Conference call scheduled for today at 8:30 am ET PRINCETON, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced results from the NEW ...